KR20230135627A - 항-PDGF-b 항체 및 폐동맥 고혈압 (PAH)을 치료하기 위한 사용 방법 - Google Patents

항-PDGF-b 항체 및 폐동맥 고혈압 (PAH)을 치료하기 위한 사용 방법 Download PDF

Info

Publication number
KR20230135627A
KR20230135627A KR1020237028422A KR20237028422A KR20230135627A KR 20230135627 A KR20230135627 A KR 20230135627A KR 1020237028422 A KR1020237028422 A KR 1020237028422A KR 20237028422 A KR20237028422 A KR 20237028422A KR 20230135627 A KR20230135627 A KR 20230135627A
Authority
KR
South Korea
Prior art keywords
pdgf
antibody
antigen
antibodies
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237028422A
Other languages
English (en)
Korean (ko)
Inventor
잉린 까오
스콧 맥도널
바라티 순다람
지 킴
이사벨라 델 프리오레
제이크 메그나
친 루안
Original Assignee
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파아마슈티컬스, 인크. filed Critical 리제너론 파아마슈티컬스, 인크.
Publication of KR20230135627A publication Critical patent/KR20230135627A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237028422A 2021-01-25 2022-01-25 항-PDGF-b 항체 및 폐동맥 고혈압 (PAH)을 치료하기 위한 사용 방법 Pending KR20230135627A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163141030P 2021-01-25 2021-01-25
US63/141,030 2021-01-25
PCT/US2022/013666 WO2022159875A1 (en) 2021-01-25 2022-01-25 Anti-pdgf-b antibodies and mehods of use for treating pulmonary arterial hypertension (pah)

Publications (1)

Publication Number Publication Date
KR20230135627A true KR20230135627A (ko) 2023-09-25

Family

ID=80446637

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237028422A Pending KR20230135627A (ko) 2021-01-25 2022-01-25 항-PDGF-b 항체 및 폐동맥 고혈압 (PAH)을 치료하기 위한 사용 방법

Country Status (13)

Country Link
US (2) US12030935B2 (https=)
EP (1) EP4281475A1 (https=)
JP (1) JP2024505195A (https=)
KR (1) KR20230135627A (https=)
CN (1) CN116964088A (https=)
AU (1) AU2022210475A1 (https=)
BR (1) BR112023014337A8 (https=)
CA (1) CA3205846A1 (https=)
CL (1) CL2023002148A1 (https=)
CO (1) CO2023010900A2 (https=)
IL (1) IL304505A (https=)
MX (1) MX2023008691A (https=)
WO (1) WO2022159875A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120028552B (zh) * 2025-02-28 2025-08-19 上海交通大学医学院附属上海儿童医学中心 血小板衍生生长因子pdgf-d在评估右心衰竭中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2136788B1 (en) 2007-03-30 2011-10-26 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
HK1216428A1 (zh) * 2012-11-09 2016-11-11 辉瑞公司 血小板衍生生长因子b之特异性抗体及其组合物和用途
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
CN107148429B (zh) 2014-11-10 2021-12-03 豪夫迈·罗氏有限公司 抗-pdgf-b抗体和使用方法

Also Published As

Publication number Publication date
US20220242943A1 (en) 2022-08-04
CL2023002148A1 (es) 2024-04-12
AU2022210475A1 (en) 2023-08-10
CO2023010900A2 (es) 2023-08-28
US20240425574A1 (en) 2024-12-26
BR112023014337A8 (pt) 2024-03-05
CA3205846A1 (en) 2022-07-28
MX2023008691A (es) 2023-08-01
EP4281475A1 (en) 2023-11-29
US12030935B2 (en) 2024-07-09
CN116964088A (zh) 2023-10-27
BR112023014337A2 (pt) 2023-09-26
JP2024505195A (ja) 2024-02-05
IL304505A (en) 2023-09-01
WO2022159875A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
JP7368543B2 (ja) 抗ｃ５抗体及びそれらの使用
JP7659501B2 (ja) ＥＧＦＲｘＣＤ２８多特異性抗体
JP6367233B2 (ja) 抗ｐｄｇｆｒ−ベータ抗体及びそれらの使用
KR102937285B1 (ko) 신규 항-pd-l1 항체
TWI756187B (zh) 抗ｌａｇ３抗體及其用途
JP5896993B2 (ja) ヒトｇｄｆ８に対する抗体
JP5832435B2 (ja) ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体
AU2019201141B2 (en) Novel antibody binding to TFPI and composition comprising the same
KR20200067833A (ko) 항-sirp-알파 항체 및 관련 방법
US20180008672A1 (en) Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
JP2020525505A (ja) 癌治療のための抗ｆａｍ１９ａ５抗体の用途
AU2020390028B2 (en) Pharmaceutical composition, preparation method therefor and use thereof
JP2025118688A (ja) ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用
WO2021063352A1 (zh) 一种抗pd-l1抗原结合蛋白及其应用
EP3504238A1 (en) Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension
KR20240021162A (ko) Alpha 5 베타 1 인테그린 결합제 및 이의 용도
US20240425574A1 (en) Anti-pdgf-b antibodies and pharmaceutical composition thereof
KR20230042273A (ko) April에 대한 항체 분자 및 그의 용도
KR20230083300A (ko) 림프계 악성 신생물 병태의 이중특이성 항체 치료
KR20220103105A (ko) 항-tim3 항체와 병용하여 항-ox40 항체를 사용한 암 치료 방법
TW202506724A (zh) 抗igf1r抗體及其用途
EA052707B1 (ru) Антитела, связывающие домен a2 фактора xi, и способы их использования
EA048356B1 (ru) МУЛЬТИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К EGFRxCD28
EA044580B1 (ru) Моноклональные анти-trkb антитела и способы их применения
EA039858B1 (ru) Антитела против c5 и их применение

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230822

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250123

Comment text: Request for Examination of Application